The BIA has submitted a letter to Guy Opperman MP as part of the Department for Work and Pensions' (DWP) consultation on Broadening the investment opportunities of defined contribution pension schemes.
The International R&D Tax Guide is a comprehensive resource designed to assist businesses in understanding and leveraging R&D tax incentives across various jurisdictions.
Nxera Pharma reports significant progress on its partnered muscarinic agonist portfolio with Neurocrine Biosciences, including plans for Phase 3 schizophrenia trials and multiple Phase 2 studies in 2025.
Johnson & Johnson has agreed to acquire Intra-Cellular Therapies for $14.6 billion, adding its innovative schizophrenia and bipolar treatment CAPLYTA® to J&J's neuroscience portfolio, along with a promising pipeline of therapies.
